Focus Partners Wealth
REGN icon

Focus Partners Wealth’s Regeneron Pharmaceuticals REGN Stock Holding History

Focus Partners Wealth’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.76M Sell
14,043
-2,398
-15% -$1.63M 0.01% 757
2026
Q1 		$12.7M Buy
16,441
+4,535
+38% +$3.47M 0.01% 640
2025
Q4 		$9.19M Buy
11,906
+2,754
+30% +$1.87M 0.01% 728
2025
Q3 		$5.15M Buy
9,152
+3,785
+71% +$2.14M 0.01% 735
2025
Q2 		$2.82M Sell
5,367
-579
-10% -$323K 0.01% 813
2025
Q1 		$3.77M Sell
5,946
-3,280
-36% -$2.26M 0.01% 707
2024
Q4 		$6.57M Buy
9,226
+6,255
+211% +$5.25M 0.02% 552
2024
Q3 		$3.12M Sell
2,971
-3,922
-57% -$4.36M 0.01% 673
2024
Q2 		$7.25M Buy
6,893
+1,900
+38% +$1.84M 0.02% 427
2024
Q1 		$4.81M Buy
4,993
+2,319
+87% +$2.21M 0.04% 328
2023
Q4 		$2.35M Buy
+2,674
New +$2.2M 0.03% 328

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Focus Partners Wealth's REGN Position: Q2 2026 in Review

Focus Partners Wealth reduced its Regeneron Pharmaceuticals (REGN) stake by 15% in Q2 2026, selling an estimated $1.63M and leaving 14,043 shares worth $8.76M. The position accounts for 0.01% of the portfolio, ranked #757.

Focus Partners Wealth first reported a position in REGN in Q4 2023 and has held it in 11 quarters since. The position peaked at $12.7M in Q1 2026. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Focus Partners Wealth held 14,043 shares of Regeneron Pharmaceuticals worth $8.76M as of Q2 2026.
  • Focus Partners Wealth sold 2,398 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $1.63M.
  • Regeneron Pharmaceuticals made up 0.01% of Focus Partners Wealth's portfolio in Q2 2026, its #757 holding.
  • Focus Partners Wealth first reported a position in Regeneron Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • Focus Partners Wealth's Regeneron Pharmaceuticals position peaked at $12.7M in Q1 2026.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Focus Partners Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.